StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)

Close on Nov 17, 2026Market cap $792.02MP/E –Yield –

Lexicon Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Lexicon Pharmaceuticals's EV/EBITDA was 14.2× on Oct 29, 2021, against 1.6× a year earlier.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2021Oct 29, 202114.2×+11.2
2020Oct 30, 20203.0×+0.8
2019Dec 31, 20192.2×−458.9
2016Apr 29, 2016461.1×–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?